[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336122-105":59,"doc-detail-336122-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","personalized-treatment-concepts-in-extraocular-cancer","Personalized treatment concepts in extraocular cancer","","Periocular malignancies in the periocular region are prone to neoplasms and are often more aggressive and harder to cure and reconstruct than cancers in other skin areas. Recent decades have advanced oncology through immunotherapy, enabling the immune system to target and destroy malignant cells. Extraocular cancers, including eyelid and conjunctival tumors, present unique clinical challenges, while targeted agents and immune checkpoint therapies offer new options. Treatment selection should depend on tumor type, size, anatomy, and molecular profile.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/personalized-treatment-concepts-in-extraocular-cancer/336122/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/personalized-treatment-concepts-in-extraocular-cancer/336122.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are periocular malignancies considered more challenging to treat?","Question",{"text":112,"@type":113},"Periocular malignancies are typically more aggressive and more difficult to cure and reconstruct than tumors in other skin areas, with substantial impact on repair and quality of life.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which molecular and immunotherapy approaches are highlighted for different extraocular cancers?",{"text":117,"@type":113},"The text links Hedgehog pathway inhibitors to basal cell carcinoma, BRAF/MEK inhibitors to melanoma, and immune checkpoint inhibitors to Merkel cell carcinoma, emphasizing the role of molecular alterations and immune engagement.",{"name":119,"@type":110,"acceptedAnswer":120},"How should optimal treatment be chosen for periocular skin cancer?",{"text":121,"@type":113},"Optimal management depends on tumor type and size and whether orbital and adnexal structures are involved. Adjuvant or neoadjuvant strategies using chemotherapy-targeted therapies and immune checkpoint inhibitors should be considered based on tumor molecular profiling, expected response rate, and eligibility for systemic treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336122,1790216831,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Advances in Ophthalmology Practice and Research 4 (2024) 69–77  \nContents lists available at ScienceDirect  \nAdvances in Ophthalmology Practice and Research  \njournal [homepage:](homepage: www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research)[ www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research](homepage: www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research)  \nReview  \nPersonalized treatment concepts in extraocular cancer  \nSitong Ju a, Alexander C. Rokohl a, b, Yongwei Guo c, Ke Yao c, Wanlin Fan a, **, Ludwig M. Heindl a, b, *  \na Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Straße, Cologne, Germany b Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany  \nc Eye Center, the Second Afﬁliated Hospital of Zhejiang University School of Medicine, Hangzhou, China  \nA R T I C L E I N F O  \nKeywords:  \nPeriocular malignancy Eyelid  \nConjunctiva tumor Immunotherapy Neoadjuvant therapy  \nA B S T R A C T  \nBackground: The periocular skin is neoplasms-prone to various benign and malignant. Periocular malignancies are more aggressive and challenging to cure and repair than those in other skin areas. In recent decades, immunotherapy has signiﬁcantly advanced oncology, allowing the autoimmune system to target and destroy malignant cells. Skin malignancies, especially periocular tumors, are particularly sensitive to immunotherapy. This technique has dramatically impacted the successful treatment of challenging tumors.  \nMain text: Extraocular cancers, including eyelid (basal cell carcinoma, squamous cell carcinoma, melanoma, merkel cell carcinoma), conjunctival tumors (conjunctival melanoma, ocular surface squamous neoplasia) and other rare tumors, are unique and challenging clinical situations. Several genetic alterations associated with the pathogenesis of these diseases have been identiﬁed, and molecular mechanism are essential for the development of the immunotherapy agents, such as Hedgehog pathway inhibitors (vismodegib and sonidegib) for basal cell carcinoma, BRAF/MEK inhibitors (vemurafenib, dabrafenib, and encorafenib) for melanoma, and immune checkpoint inhibitors (Avelumab, pembrolizumab) for Merkel cell carcinoma.  \nConclusions: The optimal treatment for periocular skin cancer depends on the type and size of the tumor and whether it involves orbital and adnexal structures. Adjuvant and neoadjuvant therapy with chemotherapytargeted therapies and immune checkpoint inhibitors should be considered based on tumor type, tumor molecular proﬁle, expected response rate, and candidacy for systemic treatment.  \n1. Introduction  \nSkin cancer frequently occurs in the periocular region due to prolonged exposure of the head and neck to ultraviolet light.1 Non-metastatic skin cancers are usually treated by radical excision or radical radiotherapy. However, these techniques have signiﬁcant morbidity and quality of life implications in the periocular region, especially for large tumors, and may be rejected by some patients. Extraocular cancers, including eyelid (basal cell carcinoma, BCC; squamous cell carcinoma, SCC; eyelid melanoma, EM; Merkel cell carcinoma, MCC) and conjunctival tumors (conjunctival melanoma,CM; ocular surface squamous neoplasia, OSSN), are unique and challenging clinical situations. Effective radical systemic therapies for these cancers are very limited and treatment outcomes are unclear. Some periocular skin  \ncancers invading the orbit may require orbital resection, which can severely affect vision and appearance and have a signiﬁcant impact on quality of life. In contrast, recent years have seen advances in the study of the molecular pathways that drive cancer development and the role of the immune system in cancer surveillance, as well as the emergence of immunotherapy and targeted therapies for locally advanced and metastatic skin cancers.2–5 These advance","cbCaiokiWUsHOlnn","https://ap.wps.com/l/cbCaiokiWUsHOlnn","pdf",684577,"English","# Review\n## Personalized treatment concepts in extraocular cancer\n## Introduction\n## Literature search","[{\"question\":\"Why are periocular malignancies considered more challenging to treat?\",\"answer\":\"Periocular malignancies are typically more aggressive and more difficult to cure and reconstruct than tumors in other skin areas, with substantial impact on repair and quality of life.\"},{\"question\":\"Which molecular and immunotherapy approaches are highlighted for different extraocular cancers?\",\"answer\":\"The text links Hedgehog pathway inhibitors to basal cell carcinoma, BRAF/MEK inhibitors to melanoma, and immune checkpoint inhibitors to Merkel cell carcinoma, emphasizing the role of molecular alterations and immune engagement.\"},{\"question\":\"How should optimal treatment be chosen for periocular skin cancer?\",\"answer\":\"Optimal management depends on tumor type and size and whether orbital and adnexal structures are involved. Adjuvant or neoadjuvant strategies using chemotherapy-targeted therapies and immune checkpoint inhibitors should be considered based on tumor molecular profiling, expected response rate, and eligibility for systemic treatment.\"}]","Personalized treatment concepts in extraocular cancer | PDF",1790013651,23]